Equities

Exact Therapeutics AS

Exact Therapeutics AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)13.00
  • Today's Change0.00 / 0.00%
  • Shares traded310.00
  • 1 Year change-31.58%
  • Beta--
Data delayed at least 15 minutes, as of Feb 01 2023.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

  • Revenue in NOK (TTM)0.00
  • Net income in NOK-57.98m
  • Incorporated2012
  • Employees8.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lifecare AS10.28m-17.86m289.36m----12.91--28.15-0.1652-0.16520.09590.19020.4309--2.26---74.86---93.53-------173.74------0.2527---70.34---508.85------
Opticept Technologies AB8.69m-75.40m301.56m----0.637--34.71-3.59-3.590.412616.550.02120.40341.13---18.51-48.78-20.04-52.0729.73131.87-874.93-840.770.9775-71.810.0701--1,532.35---396.50--54.76--
Abliva AB75.70k-100.19m309.23m8.00--1.77--4,084.80-0.2269-0.22690.00020.17210.0005--0.00179,875.00-68.89-67.30-80.31-79.05-----132,358.20-76,095.50---35.460.00---30.0960.91-105.86---43.06--
Initiator Pharma A/S0.00-58.91m309.74m----5.73-----1.29-1.290.001.080.00-------74.43-70.46-78.10-80.40------------0.2643-------142.20------
Lytix Biopharma AS1.41m-43.21m320.55m----1.89--227.50-1.12-1.120.03644.230.0072--0.2655---22.07---23.41-------3,066.50------0.00--466.67---14.16------
Biovica International AB2.78m-74.40m335.87m27.00--3.13--120.78-2.69-2.690.10072.840.0213-1.826.01116,080.00-56.94-30.85-62.19-33.47179.12332.81-2,675.53-1,470.093.20-423.610.1315---1.5426.47-51.97------
Vo2 Cap Holding AB (publ)398.49m5.73m341.33m--56.711.8918.390.85660.12180.12188.653.661.47--8.15--2.12-31.873.07-57.9522.3426.641.44-19.29--5.200.1549--46,310.78185.46-246.86------
Cereno Scientific AB0.00-22.28m355.80m----1.35-----0.2209-0.22090.002.000.00-------10.95-18.58-11.93-20.82-----------27.720.025-------1.48--54.51--
Exact Therapeutics AS0.00-57.98m389.96m8.00--2.87-----2.71-2.710.004.52------0.00--------------------0.0137-------123.18------
Alligator Bioscience AB20.01m-169.56m408.39m55.00--3.01--20.41-1.11-1.110.11290.64210.124--2.06453,978.30-105.05-33.26-145.40-36.20-----847.30-672.07----0.1175--197.40-25.981.09---58.36--
Herantis Pharma Oyj0.00-114.17m451.42m----21.59-----0.8301-0.83010.000.11350.00-------110.52-65.71-198.51-79.09-----------6.650.7896-------39.49------
ExpreS2ion Biotech Holding AB8.62m-80.87m457.68m26.00--3.21--53.09-2.39-2.390.25573.960.0545--3.28391,173.90-51.16-45.28-55.81-54.17-104.6158.57-938.00-194.44----0.0272---10.04---38.51------
Ascelia Pharma AB0.00-108.20m461.37m21.00--2.09-----3.30-3.300.006.840.00----0.00-36.47---39.44--------------0.0031-------27.57------
Nightingale Health Oyj25.20m-175.30m462.54m64.00--0.588--18.36-0.2641-0.26410.0381.850.01761.662.2236,140.63-12.23-13.89-13.06-15.6155.1784.27-695.68-354.5612.21-5.270.0661--0.34718.42-65.46------
Immunovia AB (publ)908.44k-141.73m481.46m64.00--1.70--529.98-6.54-6.540.041913.090.002158.9210.5314,584.62-32.41-24.95-35.03-26.29-7,933.23-10,942.72-15,601.05-26,830.185.66--0.1186--133.1536.63-6.80---4.73--
Mendus AB (publ)1.72m-122.99m491.08m31.00--0.9132--285.65-0.6472-0.64720.00912.810.0026--0.094559,800.00-18.38-23.81-19.01-26.35-----7,154.29-----29.220.0451-------49.48------
Data as of Feb 01 2023. Currency figures normalised to Exact Therapeutics AS's reporting currency: Norwegian Krone NOK

Institutional shareholders

6.12%Per cent of shares held by top holders
HolderShares% Held
Nordea Investment Management AB (Norway)as of 29 Jul 20221.24m4.15%
Danske Invest Asset Management ASas of 30 Dec 2022590.75k1.97%
Data from 30 Nov 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.